Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Medlab Clinical (ASX: MDC)

Last close As at 21/11/2024

6.60

— 0.00 (0.00%)

Market capitalisation

AUD15m

Latest Insights

View More

Healthcare | Outlook

Medlab Clinical — NanaBis development centre stage in 2023

Healthcare | Flash note

Medlab Clinical — Encouraging real-world data to support NanaBis

Healthcare | Flash note

Medlab Clinical — Moving closer to the Nasdaq IPO

Healthcare | Flash note

Medlab Clinical — Progressing on multiple fronts
Test tube with DNA
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (A$m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 0.0 (5.7) (52.7)
Relative 4.4 (4.0) (49.9)
52 week high/low A$19.5/A$6.5

Financials

Edison Investment Research is terminating coverage on Medlab Clinical (MDC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2021A 8.1 (11.4) (12.4) (627.0) N/A N/A
2022A 6.0 (7.4) (8.4) (314.0) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Update

Healthcare

Medlab Clinical — Transforming into a pure-play biotech

edison tv

Healthcare

Medlab Clinical – executive interview

Initiation

Healthcare

Medlab Clinical — Novel drug delivery and cannabinoids against pain

QuickView

Healthcare

Medlab Clinical — Novel drug delivery and synthetic cannabinoids